

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Kingsman et al.

Serial No. : Filed Concurrently (Divisional of 09/224,014)

For : RETROVIRAL VECTORS

Filed : Filed Concurrently

745 Fifth Avenue
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EL 819165811 US

Date of Deposit: July 25, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

Edward Nay
(Typed or printed name of person mailing paper or fee)

Edward Nay
(Signature of person mailing paper or fee)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Box Preliminary Amendment
Washington, D.C. 20231

Dear Sir:

Before the issuance of the first Office Action, please amend the above-identified application without surrender of subject matter, and without any intention of creating any

estoppel as to equivalents. A marked version of the amended portions of the application is set forth in the accompanying Appendix:

IN THE CLAIMS:

Kindly cancel all pending claims and add the following claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

-- 20. An infection and transduction competent, lentivirus-based retroviral vector particle comprising a genome, gag, pol, an envelope protein, and optionally a rev protein or functional equivalents thereof, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

21. An infection and transduction competent, lentivirus-based retroviral vector particle comprising a genome, gag, pol, and an envelope protein, wherein the particle lacks all functional lentiviral auxiliary gene products; or the particle lacks all functional lentiviral auxiliary gene products, except a rev protein or functional equivalents thereof.

22. The retroviral vector particle according to claim 20 or 21 wherein the retroviral vector particle further comprises a nucleic acid sequence which encodes one or more genes of interest.

23. The retroviral vector particle according to claim 22 wherein the gene of interest encodes a therapeutic protein.

24. An isolated cell comprising the retroviral vector particle of claim 23.

25. A composition comprising the retroviral vector particle of claim 22 and a carrier.

26. A composition comprising the retroviral vector particle of claim 23 and a carrier.

27. A method for expressing a gene of interest or replicating a nucleic acid molecule therefor comprising contacting a cell with the retroviral vector particle of claim 22.

28. A method for expressing a gene of interest comprising introducing a gene of interest into a cell by contacting said cell with the retroviral vector particle of claim 22.

29. A retroviral vector production system for producing the infection and transduction competent, lentivirus-based retroviral vector particle according to claim 20, which system comprises nucleic acid sequence(s) encoding the genome of the retroviral vector particle, gag,

pol, and the envelope protein, and optionally the rev protein or functional equivalents thereof, wherein all lentiviral auxiliary genes, or all lentiviral auxiliary genes except the optionally present *rev* or functional equivalents thereof, are absent or are disrupted, whereby functional auxiliary proteins encoded by said auxiliary genes are not expressed in the system.

30. A retroviral vector production system for producing infection and transduction competent, lentivirus-based vector particle according to claim 21, which system comprises nucleic acid sequence(s) encoding the genome of the vector particle, gag, pol, and an envelope protein, or the genome of the vector particle, gag, pol, an envelope protein, and a rev protein or functional equivalents thereof, wherein all lentiviral auxiliary genes, or all lentiviral auxiliary genes except *rev* or functional equivalents thereof, are absent or are disrupted, whereby functional auxiliary proteins encoded by said auxiliary genes are not expressed in the system.

31. The retroviral vector production system according to claim 29 or 30, wherein the nucleic acid sequence encoding the genome of the vector further comprises one or more genes of interest.

32. The retroviral vector production system according to claim 31, wherein the gene of interest encodes a therapeutic protein.

33. The retroviral vector production system according to claim 29 or 30, wherein the nucleic acid sequence(s) include three DNA constructs which encode: the genome of the vector particle, gag and pol proteins, and the envelope protein, respectively.

34. The retroviral vector production system according to claim 29 or 30, wherein the nucleic acid sequence comprises *rev* or functional equivalents thereof and RRE sequences.

35. A retroviral vector particle produced by the system according to claim 29 or 30, wherein the nucleic acid sequence encoding the genome of the vector particle further comprises one or more genes of interest.

36. A method for expressing a gene product comprising introducing a gene of interest into a cell by contacting said cell with the retroviral vector particle according to claim 35.

37. A composition comprising the retroviral vector particle according to claim 35, in a carrier.

38. An isolated cell comprising the retroviral particle of claim 35 on or in the cell.

39. The retroviral vector particle according to claim 35, wherein the gene of interest encodes a therapeutic protein.

40. A method for expressing a gene product comprising introducing a gene of interest into a cell by contacting said cell with the retroviral vector particle according to claim 39.

41. An isolated cell comprising the retroviral particle of claim 39 on or in the cell.

42. An isolated cell comprising the retroviral particle of claim 22 on or in the cell.

43. The retroviral vector particle of any one of claims 20 or 21, wherein the rev protein or functional equivalents thereof is present.

44. The retroviral vector particle of claim 22, wherein the rev protein or functional equivalents thereof is present.

45. The retroviral vector particle of claim 23, wherein the rev protein or functional equivalents thereof is present.

46. The retroviral vector particle of claim 35, wherein the rev protein or functional equivalents thereof is present.

47. The retroviral production system of any one of claims 29 or 30 wherein the genome includes an operable promoter.

48. The retroviral production system of claim 47 wherein the promoter is a non-retroviral promoter.

49. A set of nucleic acid sequences encoding the components of the infection and transduction competent, lentivirus-based vector particle according to any one of claims 20 or 21, comprising: a first DNA construct which encodes the genome of the vector particle, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes an envelope protein, wherein: one of the DNA constructs optionally encodes a rev protein or functional equivalents thereof; and all other lentiviral auxiliary gene products are absent from the retroviral vector particle and producer cells in which the sequences are expressed, and lentiviral auxiliary genes encoding said other lentiviral auxiliary gene products are absent from or disrupted in the set of sequences.

50. The set of nucleic acid sequences of claim 49, wherein *rev* or functional equivalents thereof is present.

51. The set of nucleic acid sequences of claim 49 which further comprises one or more genes of interest.

52. The set of nucleic acid sequences of claim 49 wherein the genome includes an operable promoter.

53. The set of nucleic acid sequences of claim 52 wherein the promoter is a non-retroviral promoter.

54. A method for producing the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 20 or 21, comprising coexpressing in a retroviral producer cell nucleic acid sequence(s) encoding the genome of the vector particle, gag and pol proteins, and an envelope protein, and, optionally a rev protein or functional equivalents thereof; wherein one of the nucleic acid sequence(s) optionally encodes a rev protein or functional equivalents thereof; and all other lentiviral auxiliary gene products are absent from the retroviral vector particle and producer cells in which the sequence(s) are expressed, and lentiviral auxiliary genes encoding said other lentiviral auxiliary gene products are absent from or disrupted in the sequence(s).

55. A method for producing the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 20 or 21, comprising coexpressing in a retroviral producer cell nucleic acid sequence(s) encoding the genome of the vector particle, gag and pol proteins, and an envelope protein; wherein all lentiviral auxiliary gene products are absent from the retroviral vector particle and producer cells in which the sequence(s) are expressed, and lentiviral auxiliary genes encoding said lentiviral auxiliary gene products are absent from or disrupted in the sequence(s).

56. A method for producing the infection and transduction competent, lentivirus-based, replication defective vector particle according to claim 20 or 21, consisting essentially of coexpressing in a retroviral producer cell nucleic acid sequence(s) encoding the genome of the vector particles, gag and pol proteins, and an envelope protein.

57. The method of claim 54 wherein the nucleic acid sequence(s) include one or more genes of interest.

58. The method of claim 55 wherein the nucleic acid sequence(s) include one or more genes of interest.

59. The method of claim 56 wherein the nucleic acid sequence(s) include one or more genes of interest.

60. The method of claim 54 wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes the envelope protein, wherein one of the DNA constructs optionally encodes a rev protein or functional equivalents thereof.

61. The method of claim 55 wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes the envelope protein.

62. The method of claim 56 wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes the envelope protein, wherein one of the DNA constructs optionally encodes a rev protein or functional equivalents thereof.

63. The method of claim 54 wherein the coexpressing includes expressing a DNA construct which encodes gag and pol proteins independent of auxiliary genes.

64. The method of claims 56 wherein the coexpressing includes expressing a DNA construct which encodes gag and pol proteins independent of auxiliary genes.

65. The method of claim 54 wherein *rev* is present or a rev protein or functional equivalents thereof is expressed.

66. The method of claim 56 wherein *rev* is present or a rev protein or functional equivalents thereof is expressed.

67. The method of claim 54 wherein the nucleic acid sequence(s) further includes one or more genes of interest.

68. The method of claim 55 wherein the nucleic acid sequence(s) further includes one or more genes of interest.

69. The method of claim 56 wherein the nucleic acid sequence(s) further consists essentially of one or more genes of interest.

70. The method of claim 54 wherein the genome further includes an operable promoter.

71. The method of claim 55 wherein the genome further includes an operable promoter.

72. The method of claim 56 wherein the genome further consists essentially of an operable promoter.

73. The method of claim 54 wherein the promoter is a non-retroviral promoter.

74. The method of claim 55 wherein the promoter is a non-retroviral promoter.

75. The method of claim 56 wherein the promoter is a non-retroviral promoter.

76. An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 54, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

77. An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 55, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

78. An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 56, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

79. An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 57, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

80. An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 58, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

81. An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 59, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

82. An isolated nucleic acid sequence encoding the components of the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 20 or 21, comprising DNA construct(s) which encode the genome of the vector particle, gag and pol proteins, and an envelope protein, wherein, the nucleic acid sequence produces the

lentivirus-based, replication defective vector particle, and, wherein: the DNA construct(s) optionally encode a rev protein or functional equivalents thereof; and all other functional auxiliary gene products are absent from the retroviral vector particle and producer cells in which the nucleic acid sequence is expressed, and are also absent from or disrupted in the nucleic acid sequence.

83. Isolated nucleic acid sequence(s) encoding the components of the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 20 or 21, comprising construct(s) which encode the genome of the vector particle, gag and pol proteins, and an envelope protein, wherein all functional auxiliary gene products, or all functional auxiliary gene products except rev protein or functional equivalents thereof, are absent from the retroviral vector particle and producer cells in which the nucleic acid sequence(s) is/are expressed and are absent from or disrupted in the sequence(s).

84. Isolated nucleic acid sequence(s) encoding the components of the infection and transduction competent, lentivirus-based vector particle of claim 20 or 21, consisting essentially of construct(s) which encode(s) the RNA genome of the vector particle, gag and pol proteins, and an envelope protein, wherein the construct(s) optionally encode(s) rev or functional equivalents thereof.

85. The retroviral vector production system wherein according to claim 29 or 30 wherein the retroviral vector particle is based on HIV-1 and auxiliary genes *vpu*, *vpr*, *vif*, *tat* and *nef* are absent or are disrupted.

86. The retroviral particle of claim 20 or 21 which is based on HIV-1 and auxiliary genes *vpu*, *vpr*, *vif*, *tat* and *nef* are absent or are disrupted.

87. The retroviral particle of claim 20 or 21 which is based on HIV-1 and auxiliary genes *vpu*, *vpr*, *vif*, *tat*, *rev* and *nef* are absent or are disrupted.

88. A retroviral particle according to claim 20 or 21 wherein the envelope protein is VSV-G.

89. The retroviral vector production system wherein according to claim 29 or 30 wherein rev or functional equivalents thereof is present as a constitutive transport element (CTE).

90. The retroviral particle of claim 20 or 21 wherein rev or functional equivalents thereof is present as a constitutive transport element (CTE). --

IN THE SPECIFICATION:

Please amend the specification as follows: Page 1, line 2, please insert -- This is a Divisional Application of allowed United States Patent Application No. 09/224,014, which is a Continuing Application of PCT/GB97/02857, filed October 17, 1997 and claiming priority to Great Britain Patent Application No. 9621680.9, filed October 17, 1996, and Great Britain Patent Application No. 9624457.9, filed November 25, 1996. --

Immediately after page 18 and before the first page of claims (page 19), if appropriate, please insert the enclosed pages identified as -- Sequence Listing --.

Please accept the enclosed printed version of the sequence listing, which is identical to the sequence listing submitted for parent application USSN 09/238,356, and the required Statements under 37 C.F.R. §1.821 (f) and (g) (below).

REMARKS

It is submitted that the claims herewith and the claims as originally presented are and were in full compliance with the requirements of 35 U.S.C. §§101, 102, 103 and 112. The addition and amendment of the claims herein are not made for the purpose of patentability within the meaning of 35 U.S.C. §§ 101, 102, 103 or 112; but rather the addition and amendment of the claims are made simply for clarification and to round out the scope of protection to which Applicants are entitled. Support for the amendments is found throughout the specification and from the originally-filed claims; no new matter is added.

This amendment is made to provide a lineage, including proper reference to the U.S. application of which this is a divisional application.

The Examiner's attention is respectfully drawn to the fact that the sequence listing in this application is identical to that of predecessor parent application U.S. Serial No. 09/224,014 filed June 26, 2001. It is respectfully requested that the U.S. PTO use the electronic version of the sequence listing in that prior application, making any necessary changes therein for this application, e.g., as to Serial Number and filing date.


It is believed that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R. §1.821(f) and (g) are set forth below. Pursuant to 37 C.F.R. §1.821(f), the undersigned attorney hereby states that the content of the paper copy submitted herewith, and the computer readable copy of the Sequence listing submitted in U.S.

Serial No. 09/224,014 in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same. Pursuant to 37 C.F.R. §1.821(g), the undersigned attorney of record hereby states that this submission, filed in accordance with 37 C.F.R. §1.821(g), does not contain new matter. In view of the amendments, remarks and enclosures herewith, the application complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825.

Please charge payment of fees to Deposit Account 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP



By:

Thomas J. Kowalski
Reg. No. 32,147
(212) 588-0800

09/224,014

APPENDIX 1: MARKED-UP VERSION OF AMENDMENTS

IN THE SPECIFICATION:

Specification, at page 1, the first sentence of the first paragraph (under “RELATED APPLICATIONS”):

-- This is a Divisional Application of allowed United States Patent Application No. 09/224,014, which is a Continuing Application of PCT/GB97/02857, filed October 17, 1997 and claiming priority to Great Britain Patent Application No. 9621680.9, filed October 17, 1996, and Great Britain Patent Application No. 9624457.9, filed November 25, 1996. --

IN THE CLAIMS:

-- 20. (New) An infection and transduction competent, lentivirus-based retroviral vector particle comprising a genome, gag, pol, an envelope protein, and optionally a rev protein or functional equivalents thereof, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally rev protein or functional equivalents thereof.

21. (New) An infection and transduction competent, lentivirus-based retroviral vector particle comprising a genome, gag, pol, and an envelope protein, wherein the particle lacks all functional lentiviral auxiliary gene products; or the particle lacks all functional lentiviral auxiliary gene products, except a rev protein or functional equivalents thereof.

22. (New) The retroviral vector particle according to claim 20 or 21 wherein the retroviral vector particle further comprises a nucleic acid sequence which encodes one or more genes of interest.

23. (New) The retroviral vector particle according to claim 22 wherein the gene of interest encodes a therapeutic protein.

24. (New) An isolated cell comprising the retroviral vector particle of claim 23.

25. (New) A composition comprising the retroviral vector particle of claim 22 and a carrier.

26. (New) A composition comprising the retroviral vector particle of claim 23 and a carrier.

27. (New) A method for expressing a gene of interest or replicating a nucleic acid molecule therefor comprising contacting a cell with the retroviral vector particle of claim 22.

28. (New) A method for expressing a gene of interest comprising introducing a gene of interest into a cell by contacting said cell with the retroviral vector particle of claim 22.

29. (New) A retroviral vector production system for producing the infection and transduction competent, lentivirus-based retroviral vector particle according to claim 20, which system comprises nucleic acid sequence(s) encoding the genome of the retroviral vector particle, gag, pol, and the envelope protein, and optionally the rev protein or functional equivalents thereof, wherein all lentiviral auxiliary genes, or all lentiviral auxiliary genes except the optionally present *rev* or functional equivalents thereof, are absent or are disrupted, whereby functional auxiliary proteins encoded by said auxiliary genes are not expressed in the system.

30. (New) A retroviral vector production system for producing infection and transduction competent, lentivirus-based vector particle according to claim 21, which system comprises nucleic acid sequence(s) encoding the genome of the vector particle, gag, pol, and an envelope protein, or the genome of the vector particle, gag, pol, an envelope protein, and a rev protein or functional equivalents thereof, wherein all lentiviral auxiliary genes, or all lentiviral auxiliary genes except *rev* or functional equivalents thereof, are absent or are disrupted, whereby functional auxiliary proteins encoded by said auxiliary genes are not expressed in the system.

31. (New) The retroviral vector production system according to claim 29 or 30, wherein the nucleic acid sequence encoding the genome of the vector further comprises one or more genes of interest.

32. (New) The retroviral vector production system according to claim 31, wherein the gene of interest encodes a therapeutic protein.

33. (New) The retroviral vector production system according to claim 29 or 30, wherein the nucleic acid sequence(s) include three DNA constructs which encode: the genome of the vector particle, gag and pol proteins, and the envelope protein, respectively.

34. (New) The retroviral vector production system according to claim 29 or 30, wherein the nucleic acid sequence comprises *rev* or functional equivalents thereof and RRE sequences.

35. (New) A retroviral vector particle produced by the system according to claim 29 or 30, wherein the nucleic acid sequence encoding the genome of the vector particle further comprises one or more genes of interest.

36. (New) A method for expressing a gene product comprising introducing a gene of interest into a cell by contacting said cell with the retroviral vector particle according to claim 35.

37 (New) A composition comprising the retroviral vector particle according to claim 35, in a carrier.

38. (New) An isolated cell comprising the retroviral particle of claim 35 on or in the cell.

39. (New) The retroviral vector particle according to claim 35, wherein the gene of interest encodes a therapeutic protein.

40. (New) A method for expressing a gene product comprising introducing a gene of interest into a cell by contacting said cell with the retroviral vector particle according to claim 39.

41. (New) An isolated cell comprising the retroviral particle of claim 39 on or in the cell.

42. (New) An isolated cell comprising the retroviral particle of claim 22 on or in the cell.

43. (New) The retroviral vector particle of any one of claims 20 or 21, wherein the rev protein or functional equivalents thereof is present.

44. (New) The retroviral vector particle of claim 22, wherein the rev protein or functional equivalents thereof is present.

45. (New) The retroviral vector particle of claim 23, wherein the rev protein or functional equivalents thereof is present.

46. (New) The retroviral vector particle of claim 35, wherein the rev protein or functional equivalents thereof is present.

47. (New) The retroviral production system of any one of claims 29 or 30 wherein the genome includes an operable promoter.

48. (New) The retroviral production system of claim 47 wherein the promoter is a non-retroviral promoter.

49. (New) A set of nucleic acid sequences encoding the components of the infection and transduction competent, lentivirus-based vector particle according to any one of claims 20 or 21, comprising: a first DNA construct which encodes the genome of the vector particle, a second

DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes an envelope protein, wherein: one of the DNA constructs optionally encodes a rev protein or functional equivalents thereof; and all other lentiviral auxiliary gene products are absent from the retroviral vector particle and producer cells in which the sequences are expressed, and lentiviral auxiliary genes encoding said other lentiviral auxiliary gene products are absent from or disrupted in the set of sequences.

50. (New) The set of nucleic acid sequences of claim 49, wherein *rev* or functional equivalents thereof is present.

51. (New) The set of nucleic acid sequences of claim 49 which further comprises one or more genes of interest.

52. (New) The set of nucleic acid sequences of claim 49 wherein the genome includes an operable promoter.

53. (New) The set of nucleic acid sequences of claim 52 wherein the promoter is a non-retroviral promoter.

54. (New) A method for producing the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 20 or 21, comprising coexpressing in a retroviral producer cell nucleic acid sequence(s) encoding the genome of the vector particle, gag and pol proteins, and an envelope protein, and, optionally a rev protein or functional equivalents thereof; wherein one of the nucleic acid sequence(s) optionally encodes a rev protein or functional equivalents thereof; and all other lentiviral auxiliary gene products are absent from the retroviral vector particle and producer cells in which the sequence(s) are expressed, and lentiviral auxiliary genes encoding said other lentiviral auxiliary gene products are absent from or disrupted in the sequence(s).

55. (New) A method for producing the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 20 or 21, comprising coexpressing in a retroviral producer cell nucleic acid sequence(s) encoding the genome of the vector particle, gag and pol proteins, and an envelope protein; wherein all lentiviral auxiliary gene products are absent from the retroviral vector particle and producer cells in which the sequence(s) are expressed, and lentiviral auxiliary genes encoding said lentiviral auxiliary gene products are absent from or disrupted in the sequence(s).

56. (New) A method for producing the infection and transduction competent, lentivirus-based, replication defective vector particle according to claim 20 or 21, consisting essentially of coexpressing in a retroviral producer cell nucleic acid sequence(s) encoding the genome of the vector particles, gag and pol proteins, and an envelope protein.

57. (New) The method of claim 54 wherein the nucleic acid sequence(s) include one or more genes of interest.

58. (New) The method of claim 55 wherein the nucleic acid sequence(s) include one or more genes of interest.

59. (New) The method of claim 56 wherein the nucleic acid sequence(s) include one or more genes of interest.

60. (New) The method of claim 54 wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes the envelope protein, wherein one of the DNA constructs optionally encodes a rev protein or functional equivalents thereof.

61. (New) The method of claim 55 wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes the envelope protein.

62. (New) The method of claim 56 wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes the envelope protein, wherein one of the DNA constructs optionally encodes a rev protein or functional equivalents thereof.

63. (New) The method of claim 54 wherein the coexpressing includes expressing a DNA construct which encodes gag and pol proteins independent of auxiliary genes.

64. (New) The method of claims 56 wherein the coexpressing includes expressing a DNA construct which encodes gag and pol proteins independent of auxiliary genes.

65. (New) The method of claim 54 wherein *rev* is present or a rev protein or functional equivalents thereof is expressed.

66. (New) The method of claim 56 wherein *rev* is present or a rev protein or functional equivalents thereof is expressed.

67. (New) The method of claim 54 wherein the nucleic acid sequence(s) further includes one or more genes of interest.

68. (New) The method of claim 55 wherein the nucleic acid sequence(s) further includes one or more genes of interest.

69. (New) The method of claim 56 wherein the nucleic acid sequence(s) further consists essentially of one or more genes of interest.

70. (New) The method of claim 54 wherein the genome further includes an operable promoter.

71. (New) The method of claim 55 wherein the genome further includes an operable promoter.

72. (New) The method of claim 56 wherein the genome further consists essentially of an operable promoter.

73. (New) The method of claim 54 wherein the promoter is a non-retroviral promoter.

74. (New) The method of claim 55 wherein the promoter is a non-retroviral promoter.

75. (New) The method of claim 56 wherein the promoter is a non-retroviral promoter.

76. (New) An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 54, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

77. (New) An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 55, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

78. (New) An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 56, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

79. (New) An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 57, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

80. (New) An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 58, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

81. (New) An infection and transduction competent, lentivirus-based, replication defective vector particle produced by the method of claim 59, wherein the particle lacks all functional lentiviral auxiliary gene products other than the optionally present rev protein or functional equivalents thereof.

82. (New) An isolated nucleic acid sequence encoding the components of the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 20 or 21, comprising DNA construct(s) which encode the genome of the vector particle, gag and pol proteins, and an envelope protein, wherein, the nucleic acid sequence produces the lentivirus-based, replication defective vector particle, and, wherein: the DNA construct(s) optionally encode a rev protein or functional equivalents thereof; and all other functional auxiliary gene products are absent from the retroviral vector particle and producer cells in which the nucleic acid sequence is expressed, and are also absent from or disrupted in the nucleic acid sequence.

83. (New) Isolated nucleic acid sequence(s) encoding the components of the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 20 or 21, comprising construct(s) which encode the genome of the vector particle, gag and pol proteins, and an envelope protein, wherein all functional auxiliary gene products, or all functional auxiliary gene products except rev protein or functional equivalents thereof, are absent from the retroviral vector particle and producer cells in which the nucleic acid sequence(s) is/are expressed and are absent from or disrupted in the sequence(s).

84. (New) Isolated nucleic acid sequence(s) encoding the components of the infection and transduction competent, lentivirus-based vector particle of claim 20 or 21, consisting essentially of construct(s) which encode(s) the RNA genome of the vector particle,

gag and pol proteins, and an envelope protein, wherein the construct(s) optionally encode(s) rev or functional equivalents thereof.

85. (New) The retroviral vector production system wherein according to claim 29 or 30 wherein the retroviral vector particle is based on HIV-1 and auxiliary genes *vpu*, *vpr*, *vif*, *tat* and *nef* are absent or are disrupted.

86. (New) The retroviral particle of claim 20 or 21 which is based on HIV-1 and auxiliary genes *vpu*, *vpr*, *vif*, *tat* and *nef* are absent or are disrupted.

87. (New) The retroviral particle of claim 20 or 21 which is based on HIV-1 and auxiliary genes *vpu*, *vpr*, *vif*, *tat*, *rev* and *nef* are absent or are disrupted.

88. (New) A retroviral particle according to claim 20 or 21 wherein the envelope protein is VSV-G.

89. (New) The retroviral vector production system wherein according to claim 29 or 30 wherein rev or functional equivalents thereof is present as a constitutive transport element (CTE).

90. (New) The retroviral particle of claim 20 or 21 wherein rev or functional equivalents thereof is present as a constitutive transport element (CTE). --

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : KINGSMAN et al..
U.S. Serial No. : 09/224,014
Filing Date : December 28, 1998
For : RETROVIRAL VECTORS
Examiner : Dave Nguyen
Art Unit : 1633

745 Fifth Avenue
New York, NY 10151

HAND DELIVERED

AMENDMENT ENCLOSING SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed are:

1. Return-receipt postcard;
2. Diskette; and
3. Sequence listing

Please amend the application as follows:

IN THE SPECIFICATION

Please cancel the original paper copy entitled --Sequence Listing--.

Immediately after page 18 and before the first page of claims (page 19), if appropriate,
please insert the enclosed pages identified as --Sequence Listing--.

The PTO did not receive the following
listed item(s) Diskette

REMARKS

It is believed that the Sequence Listing conforms to the requirements of the 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R. §1.821 (f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821 (g), the undersigned attorney of record hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821 (f), the undersigned attorney hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same.

No new matter is added by the specification amendments herewith.

In view of the amendments, remarks and enclosures herewith, the application complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825. Please charge any additional fees incurred by reason of this Response to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By: Marilyn M. Brogan
Marilyn M. Brogan
Reg. No. 31,223
(212) 588-0800

Enclosures: Paper and Disk Sequence Listing
Return-receipt postcard